Trougakos Ioannis P, Lourda Magda, Antonelou Marianna H, Kletsas Dimitris, Gorgoulis Vassilis G, Papassideri Issidora S, Zou Yonglong, Margaritis Lukas H, Boothman David A, Gonos Efstathios S
Laboratory of Molecular and Cellular Aging, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece.
Clin Cancer Res. 2009 Jan 1;15(1):48-59. doi: 10.1158/1078-0432.CCR-08-1805.
Secretory clusterin (sCLU)/apolipoprotein J is an extracellular chaperone that has been functionally implicated in DNA repair, cell cycle regulation, apoptotic cell death, and tumorigenesis. It exerts a prosurvival function against most therapeutic treatments for cancer and is currently an antisense target in clinical trials for tumor therapy. However, the molecular mechanisms underlying its function remained largely unknown.
The molecular effects of small interfering RNA-mediated sCLU depletion in nonstressed human cancer cells were examined by focusing entirely on the endogenously expressed sCLU protein molecules and combining molecular, biochemical, and microscopic approaches.
We report here that sCLU depletion in nonstressed human cancer cells signals stress that induces p53-dependent growth retardation and high rates of endogenous apoptosis. We discovered that increased apoptosis in sCLU-depleted cells correlates to altered ratios of proapoptotic to antiapoptotic Bcl-2 protein family members, is amplified by p53, and is executed by mitochondrial dysfunction. sCLU depletion-related stress signals originate from several sites, because sCLU is an integral component of not only the secretory pathway but also the nucleocytosolic continuum and mitochondria. In the cytoplasm, sCLU depletion disrupts the Ku70-Bax complex and triggers Bax activation and relocation to mitochondria. We show that sCLU binds and thereby stabilizes the Ku70-Bax protein complex serving as a cytosol retention factor for Bax.
We suggest that elevated sCLU levels may enhance tumorigenesis by interfering with Bax proapoptotic activities and contribute to one of the major characteristics of cancer cells, that is, resistance to apoptosis.
分泌型簇集素(sCLU)/载脂蛋白J是一种细胞外伴侣蛋白,在DNA修复、细胞周期调控、凋亡性细胞死亡和肿瘤发生过程中发挥功能作用。它对大多数癌症治疗方法具有促生存功能,目前是肿瘤治疗临床试验中的一个反义靶点。然而,其功能背后的分子机制在很大程度上仍不清楚。
通过完全聚焦于内源性表达的sCLU蛋白分子,并结合分子、生化和显微镜方法,研究了小干扰RNA介导的sCLU缺失在未受应激的人类癌细胞中的分子效应。
我们在此报告,未受应激的人类癌细胞中sCLU缺失会发出应激信号,诱导p53依赖的生长迟缓以及高比率的内源性凋亡。我们发现,sCLU缺失细胞中凋亡增加与促凋亡和抗凋亡Bcl-2蛋白家族成员比例改变相关,由p53放大,并通过线粒体功能障碍执行。sCLU缺失相关的应激信号源自多个部位,因为sCLU不仅是分泌途径的一个组成部分,也是核质连续体和线粒体的组成部分。在细胞质中,sCLU缺失会破坏Ku70-Bax复合物,触发Bax激活并重新定位于线粒体。我们表明,sCLU结合并因此稳定了Ku70-Bax蛋白复合物,该复合物作为Bax的胞质保留因子。
我们认为,sCLU水平升高可能通过干扰Bax的促凋亡活性增强肿瘤发生,并促成癌细胞的主要特征之一,即对凋亡的抗性。